Korea Republic Of

Daewoong Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Daewoong to Conduct Phase 1 trial of Covid-19 Treatment in Indonesia

Lead Product(s): DWP710

Therapeutic Area: Infections and Infectious Diseases Product Name: DWP710

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 06, 2020

Details:

To investigate the anti-inflammatory effect of DWP710, the company had tested an animal model with acute respiratory distress syndrome using the inflammatory inducer lipopolysaccharide.

JW Pharmaceutical Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

JW Pharmaceutical to Repurpose Targeted Oncology Drug as COVID-19 Therapy

Lead Product(s): CWP291

Therapeutic Area: Infections and Infectious Diseases Product Name: CWP291

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 17, 2020

Details:

CWP291 is a Wnt/beta-catenin inhibitor that is under development as a first-in-class treatment for acute myeloid leukemia, multiple myeloma and stomach cancer.

Daewoong Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Daewoong Finds Niclosamide Effective Against Covid-19 in Animal Tests

Lead Product(s): Niclosamide

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 10, 2020

Details:

The company added that the drug completely cleared the infection in ferrets’ lung tissues and inhibited inflammation, according to Reuters. The testing on ferrets was carried out for approximately three months.

Celltrion

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

South Korea's Celltrion Aims to Start In-Human COVID-19 Drug Trial in July

Lead Product(s): COVID-19 antiviral antibody

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2020

Details:

Pre-clinical data for Celltrion’s antiviral antibody treatment candidate demonstrate a 100-fold reduction in viral load of SARS-CoV-2 (COVID-19), as well as improvement in lung lesions.

Genexine, Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Kalbe to Start COVID-19 Vaccine Trial with S. Korean Pharma Firm

Lead Product(s): GX-19

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: PT Kalbe Farma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 27, 2020

Details:

Under the terms of the MOU, Kalbe and Genexine has agreed to conduct GX-19 clinical trials in Indonesia, that is the development of DNA vaccines against the new corona virus.

Genexine, Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Genexine Consortium Develops COVID-19 Vaccine for Human Testing

Lead Product(s): GX-19

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2020

Details:

GX-19 is a potential COVID-19 vaccine developed based on Genexine’s DNA vaccine know-how. The consortium will apply for clinical testing of GX-19 within May, and is expecting to begin testing the vaccine on patients starting early June.

DongWha Pharm

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

DongWha Pharm to Kick Off Trials for Virus Treatment

Lead Product(s): DW2008

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 06, 2020

Details:

In vitro antiviral experiments performed against COVID-19 demonstrated that DW2008 had 1.7, 3.8, and 4.7 times higher antiviral activity compared to chloroquine, remdesivir, and Kaletra respectively.